Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MACK
  • CUSIP: 59032810
  • Web:
  • Market Cap: $455.55 million
  • Outstanding Shares: 132,427,000
Average Prices:
  • 50 Day Moving Avg: $3.33
  • 200 Day Moving Avg: $3.86
  • 52 Week Range: $2.83 - $7.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.71
  • P/E Growth: -1.11
Sales & Book Value:
  • Annual Revenue: $144.27 million
  • Price / Sales: 3.16
  • Book Value: ($2.09) per share
  • Price / Book: -1.65
  • EBIDTA: ($88,040,000.00)
  • Net Margins: -160.00%
  • Return on Assets: -96.01%
  • Debt-to-Equity Ratio: -0.96%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.85%
  • Average Volume: 2.00 million shs.
  • Beta: 1.92
  • Short Ratio: 13.8

Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared an annual dividend on Friday, April 7th. Investors of record on Wednesday, May 17th will be paid a dividend of $1.06 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.15. During the same quarter in the prior year, the company earned ($0.33) EPS. View Merrimack Pharmaceuticals' Earnings History.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 1-year price objectives for Merrimack Pharmaceuticals' stock. Their predictions range from $5.00 to $13.00. On average, they anticipate Merrimack Pharmaceuticals' share price to reach $8.33 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.

What are analysts saying about Merrimack Pharmaceuticals stock?

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Merrimack reported a wider-than-expected loss in the quarter and generated no revenue as it sold Onivyde to Ipsen. With the sale of Onivyde, the company is back to being a development-stage biopharmaceutical company. Thus, the successful development of the three lead candidates in its pipeline is critical for Merrimack’s growth. Moreover, two of the candidates, MM-121 and MM-141, are still being evaluated in phase II studies. And the third candidate, MM-310 entered phase I study in the first quarter of 2017. Also, shares of the company have underperformed the Zacks categorized Medical Biomed/Genetics industry year to date. However, the cash received from Ipsen will be used to pay down the huge debt and return value to shareholders in the form of dividends." (5/15/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totalling 22,373,586 shares, a drop of 10.3% from the April 28th total of 24,938,481 shares. Based on an average daily trading volume, of 1,791,349 shares, the short-interest ratio is presently 12.5 days. Currently, 18.1% of the shares of the company are sold short.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.80%), Vanguard Group Inc. (7.86%), State Street Corp (5.06%), TIAA CREF Investment Management LLC (4.89%), Teachers Advisors LLC (1.44%) and Geode Capital Management LLC (0.77%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Ulrik B Nielsen, Vivian S Lee, William A Sullivan and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P., Teachers Advisors LLC, Morgan Stanley, AXA, FMR LLC, Alliancebernstein L.P., UBS Group AG and Stoneridge Investment Partners LLC. Company insiders that have sold Merrimack Pharmaceuticals stock in the last year include Birgit M Schoeberl and Daryl C Drummond. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Candriam Luxembourg S.C.A., Yakira Capital Management Inc., Credit Suisse AG, Kempner Capital Management Inc., Cornerstone Capital Management Holdings LLC. and Airain ltd. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merrimack Pharmaceuticals stock cost?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $3.44.

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $8.33 (142.25% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
1/11/2017Robert W. BairdReiterated RatingNeutral$5.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00N/AView Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.07)($0.22)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($0.21)($0.25)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($0.27)($0.23)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.30)($0.32)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.12)($0.27)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.32)($0.17)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($0.31)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.57 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS


Dividend History by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 73.14%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline logoMerrimack Pharmaceuticals Inc (MACK) Given "Market Perform" Rating at Cowen and Company - May 19 at 10:18 PM logoMerrimack Pharmaceuticals Inc (MACK) Upgraded to Hold at Zacks Investment Research - May 15 at 12:24 PM logoInsider Selling: Merrimack Pharmaceuticals Inc (MACK) Insider Sells 4,097 Shares of Stock - May 12 at 8:26 PM logoEdited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT - May 11 at 6:56 PM logoMerrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde - May 11 at 6:56 PM
News IconBRIEF-Merrimack reports Q1 loss per share $0.23 - May 11 at 4:03 AM logoMerrimack Reports First Quarter 2017 Financial Results - PR Newswire (press release) - May 10 at 5:58 PM logoMerrimack Pharmaceuticals Inc (MACK) Releases Earnings Results, Misses Expectations By $0.11 EPS - May 10 at 3:52 PM logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss - May 10 at 12:41 PM logoEarnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 4.2% Sensitive - May 10 at 12:41 PM logoMerrimack Reports First Quarter 2017 Financial Results - May 10 at 12:41 PM logoInvestor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call - May 10 at 12:41 PM logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss - May 10 at 12:41 PM logoMerrimack reports 1Q loss - May 10 at 7:04 AM logoMerrimack Pharmaceuticals (MACK) Receiving Somewhat Negative Press Coverage, Study Finds - May 3 at 9:48 AM logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call - PR Newswire (press release) - May 3 at 8:20 AM logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call - May 2 at 7:51 PM logoMerrimack Pharmaceuticals Inc (MACK) Given Average Rating of "Hold" by Analysts - May 2 at 2:48 PM logoMerrimack Pharmaceuticals Inc (MACK) Downgraded by Zacks Investment Research - May 2 at 1:56 PM logoSomewhat Positive Media Coverage Very Unlikely to Impact Merrimack Pharmaceuticals (MACK) Stock Price - April 27 at 11:38 PM logoWhat's in the Cards for Merrimack (MACK) in Q1 Earnings? - April 27 at 6:57 PM logoMerrimack Pharmaceuticals (MACK) Getting Somewhat Favorable Media Coverage, Study Finds - April 23 at 8:55 PM logoMerrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : April 19, 2017 - April 19 at 6:30 PM logoMerrimack Pharmaceuticals (MACK) Receiving Somewhat Favorable Press Coverage, Analysis Finds - April 18 at 8:53 PM logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017 - April 18 at 10:33 AM logoMerrimack Appoints Daryl Drummond, Ph.D. as Head of Research - PR Newswire (press release) - April 17 at 10:20 AM logoMerrimack Appoints Daryl Drummond, Ph.D. as Head of Research - April 17 at 10:20 AM logoMerrimack: Does Special Dividend In May Present A Buying Opportunity? - April 12 at 7:20 PM logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 4, 2017 - April 7 at 11:02 AM logoMerrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale - April 7 at 11:02 AM logoMerrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance … - April 4 at 9:04 AM logoBRIEF-Merrimack completes ONIVYDE sale to Ipsen - April 4 at 9:04 AM logoMerrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310 - April 4 at 9:04 AM logoIntezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium - April 2 at 10:18 AM logoMerrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion - PR Newswire (press release) - April 1 at 12:00 PM logoAre Options Traders Betting on a Big Move in Merrimack (MACK) Stock? - March 31 at 9:47 AM logoBRIEF-Merrimack stockholders approve Onivyde, generic Doxil sale to Ipsen - March 30 at 6:43 PM logoMerrimack Pharma (MACK) Sale of ONIVYDE® & Generic Version of DOXIL® to Ipsen for Up to $1.025B Approved by Shareholders - March 30 at 6:43 PM logoMerrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion - March 30 at 6:43 PM logo12:02 pm Merrimack Pharma stockholders vote to approve the asset sale of ONIVYDE and the genereic verison of DOXIL to Ipsen S.A. (IPSEY) for up to $1.025 bln - March 30 at 6:43 PM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - March 30 at 6:43 PM logoMerrimack Pharmaceuticals Inc (MACK) Receives Average Recommendation of "Buy" from Brokerages - March 30 at 1:22 PM logoMerrimack to Present at the 2017 American Association for Cancer Research Annual Meeting - March 27 at 10:32 AM logoMerrimack Pharmaceuticals Inc (MACK) Short Interest Down 8.7% in March - March 27 at 7:04 AM logoMerrimack Initiates Phase 1 Study of MM-310 in Solid Tumors - PR Newswire (press release) - March 25 at 9:22 AM logo​Merrimack asset sale prompts legal blowback - March 23 at 6:58 PM logoBRIEF-Merrimack Pharmaceuticals reports enrollment of 1st patient in phase 1 study of mm-310 - March 23 at 8:53 AM logoMerrimack Initiates Phase 1 Study of MM-310 in Solid Tumors - March 23 at 8:53 AM logoLawyer: former Merrimack employee accused of insider trading to fight charges - March 22 at 9:34 AM logoMerrimack Pharmaceuticals Inc (MACK) Sees Large Growth in Short Interest - March 10 at 11:04 AM



Merrimack Pharmaceuticals (MACK) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff